142 related articles for article (PubMed ID: 34712610)
1. Tumor DNA From Tumor
Yu J; Sheng Z; Wu S; Gao Y; Yan Z; Bu C; Gu J; Bu Y; Deng K; Xu S; Chen Z; Zhang Q; Zemmar A; Hernesniemi J; Wang M; Liu G; Li T; Bu X
Front Oncol; 2021; 11():742037. PubMed ID: 34712610
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the Genomic Landscape of Brain Glioma With Circulating Tumor DNA From Tumor
Sheng Z; Yu J; Deng K; Andrade-Barazarte H; Zemmar A; Li S; Li N; Yan Z; Chen Z; Sun Y; Hernesniemi J; Bu X
Front Oncol; 2021; 11():584988. PubMed ID: 33868989
[TBL] [Abstract][Full Text] [Related]
3. Tracking tumor evolution during the first-line treatment in brain glioma
Sheng Z; Bu C; Mei J; Xu S; Zhang Z; Guo G; Gao Y; Xing L; Chen Z; Hernesniemi J; Zemmar A; Bu X
Front Oncol; 2023; 13():1238607. PubMed ID: 37920153
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: Close to the clinic?
Simonelli M; Dipasquale A; Orzan F; Lorenzi E; Persico P; Navarria P; Pessina F; Nibali MC; Bello L; Santoro A; Boccaccio C
Crit Rev Oncol Hematol; 2020 Feb; 146():102879. PubMed ID: 32005411
[TBL] [Abstract][Full Text] [Related]
5. FLAIR signal increase of the fluid within the resection cavity after glioma surgery: generally valid as early recurrence marker?
Bette S; Gempt J; Huber T; Delbridge C; Meyer B; Zimmer C; Kirschke JS; Boeckh-Behrens T
J Neurosurg; 2017 Aug; 127(2):417-425. PubMed ID: 27767397
[TBL] [Abstract][Full Text] [Related]
6. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
7. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients.
Shi R; Wang PY; Li XY; Chen JX; Li Y; Zhang XZ; Zhang CG; Jiang T; Li WB; Ding W; Cheng SJ
Oncotarget; 2015 Sep; 6(29):26971-81. PubMed ID: 26284486
[TBL] [Abstract][Full Text] [Related]
8.
Wang Z; Jiang W; Wang Y; Guo Y; Cong Z; DU F; Song B
Biomed Rep; 2015 Jul; 3(4):543-548. PubMed ID: 26171163
[TBL] [Abstract][Full Text] [Related]
9. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
[No Abstract] [Full Text] [Related]
10. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma.
Escudero L; Llort A; Arias A; Diaz-Navarro A; Martínez-Ricarte F; Rubio-Perez C; Mayor R; Caratù G; Martínez-Sáez E; Vázquez-Méndez É; Lesende-Rodríguez I; Hladun R; Gros L; Ramón Y Cajal S; Poca MA; Puente XS; Sahuquillo J; Gallego S; Seoane J
Nat Commun; 2020 Oct; 11(1):5376. PubMed ID: 33110059
[TBL] [Abstract][Full Text] [Related]
12. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas.
Berger MS; Deliganis AV; Dobbins J; Keles GE
Cancer; 1994 Sep; 74(6):1784-91. PubMed ID: 8082081
[TBL] [Abstract][Full Text] [Related]
13. Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers.
Arcella A; Limanaqi F; Ferese R; Biagioni F; Oliva MA; Storto M; Fanelli M; Gambardella S; Fornai F
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31968687
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma.
Liu Z; Lu T; Wang L; Liu L; Li L; Han X
Front Mol Biosci; 2021; 8():682084. PubMed ID: 34307451
[No Abstract] [Full Text] [Related]
15. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
16. Identifying molecular markers for the sensitive detection of residual atypical teratoid rhabdoid tumor cells.
Vu-Han TL; Frühwald MC; Hasselblatt M; Kerl K; Nagel I; Obser T; Oyen F; Siebert R; Schneppenheim R
Cancer Genet; 2014 Sep; 207(9):390-7. PubMed ID: 25016934
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma.
Shee K; Chambers M; Hughes EG; Almiron DA; Deharvengt SJ; Green D; Lefferts JA; Andrew AS; Hickey WF; Tsongalis GJ
J Neurooncol; 2020 Jul; 148(3):473-480. PubMed ID: 32583303
[TBL] [Abstract][Full Text] [Related]
18. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma.
Sampath P; Weaver CE; Sungarian A; Cortez S; Alderson L; Stopa EG
Cancer Control; 2004; 11(3):174-80. PubMed ID: 15153841
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
